Market research
For country-by-country execution pathways, start from the healthcare market research hub.
Qatar
Market
AR + EN
Fieldwork
48h
to a proposal
48
countries
Context
Qatar programs reflect Ministry of Public Health registration requirements and Hamad Medical Corporation procurement pathways that differ from UAE emirate-level logic.
Private insurance and Sidra Medicine networks add parallel access routes; sampling should mirror where your therapy is realistically listed.
MOPH's drug registration and pricing approval process runs on its own timeline independent of SFDA or MOHAP, and Gulf-wide registration does not guarantee Qatar listing at the same pace. We track MOPH-specific milestones separately so launch sequencing plans are not built on borrowed assumptions from a neighbouring market.
HMC's centralized pharmacy and therapeutics committee effectively functions as the country's primary formulary gatekeeper for public-sector patients, and understanding how that committee weighs clinical versus budget evidence is often more valuable to a sponsor than a broad physician opinion survey.
Qatar's national health strategy has continued to invest in specialty capacity and digital health infrastructure, which is gradually changing how quickly new therapies reach practising physicians once registered. Research programmes should confirm current infrastructure status rather than relying on assumptions from a few years ago, since the pace of change has been material.
Mandatory visitor and resident health insurance requirements mean nearly all patients carry some form of coverage, but the depth of that coverage — and therefore willingness-to-pay behaviour — varies considerably between comprehensive employer plans and minimum-compliance policies. Access research should account for this range rather than assuming uniform coverage depth.
Where a sponsor needs HMC facility-level access for chart review or on-site observation, formal institutional approval is typically required and can take longer to secure than similar approvals in a more fragmented multi-provider system. Building this timeline into the project plan early avoids a mid-study delay that catches sponsors off guard and forces a scramble to explain a slipped delivery date.
Qatar is a compact but high-spend GCC market with concentrated specialist care in Doha referral networks.
Cross-border benchmarking with UAE and Saudi Arabia is common; instruments should stay comparable while preserving MOPH nuance.
The country's high proportion of expatriate residents relative to citizens means healthcare access and coverage vary significantly by employment sector and visa status, and demand models should reflect that split rather than treating the resident population as homogeneous.
Distribution runs through a small number of licensed wholesalers and pharmacy groups, concentrating commercial relationships in a way that rewards account-level intelligence over broad market surveys for institutional brands.
Doha's hospital and clinic footprint has expanded with new private facilities entering specialty and elective care, gradually diversifying a market that was until recently almost entirely defined by HMC. Sponsors evaluating a private-channel strategy should treat this as an emerging rather than mature segment, with adoption patterns still forming and worth revisiting on a regular cadence rather than assuming last year's findings still hold.
As a hub for medical tourism and regional referral for certain specialty procedures, Qatar's addressable population for some categories extends beyond its resident base, which sizing models should account for explicitly rather than ignoring cross-border demand entirely.
Government investment in genomics and precision medicine infrastructure has created early demand for research support around novel diagnostic and targeted therapy categories, an area where Qatar has moved faster than some larger Gulf neighbours relative to its population size and available specialist capacity.
Adoption, sequencing, and message testing.
Formulary and committee objection mapping.
Influence networks for specialty launches.
Qatar cell inside multi-country programs.
Understanding pharmacy and therapeutics committee priorities and evidence expectations.
Dedicated outreach for pediatric, maternal, and women's health categories treated at Sidra.
Tracking adoption and pricing sensitivity for privately insured expatriate and resident segments.
Evaluating adoption patterns as new private specialty and elective care facilities expand in Doha.
Accounting for regional patients referred into Qatar for specific specialty procedures.
Decision-led mixed-method design with bilingual QC and scarcity-aware recruitment calendars.
Outputs map to one commercial or access decision per phase.
Given how concentrated Qatar's specialist community is, we validate feasibility — how many named specialists realistically treat a given condition — before committing to a quantitative sample size, and we recommend a qualitative-led design where that population is very small.
Recruitment lists draw on verified HMC and Sidra rosters plus professional society membership rather than generic contact databases, since a compact market like Qatar is especially sensitive to stale or duplicate contacts skewing results in a way larger markets can absorb more easily.
Where a study needs to separate public and private channel behaviour, we build distinct screener logic for each rather than blending HMC and private-hospital respondents into a single sample that obscures where the real access difference lies.
Every deliverable maps explicitly back to the original scoping decision, and any secondary finding that would not change that decision is documented as context rather than presented as an actionable recommendation.
For genomics and precision medicine categories, we work with sponsors to identify the small number of specialists and laboratory leads with genuine hands-on experience, since general physician panels typically lack the technical depth needed to evaluate these newer diagnostic and treatment approaches in a meaningful way.
Oncology, diabetes, and immunology are frequent priorities in Qatar research programs. Pediatric and maternal health categories carry particular weight given Sidra Medicine's specialized focus, and research in these areas is scoped with its own stakeholder map rather than folded into general HMC assumptions. Cardiometabolic disease burden is high nationally, which keeps demand for cardiology and diabetes research consistently strong across both public and private channels.
Decision gate, therapy, and stakeholder map.
Bilingual execution with weekly checkpoints.
Leadership readout and 30/60/90 actions.
Early confirmation of specialist pool size at HMC and Sidra before a full quantitative sample is committed.
Optional follow-up waves for sponsors tracking committee decisions or new entrants in a therapy area.
Optional module comparing HMC, Sidra, and private-hospital adoption patterns side by side for the same therapy.
Compact markets require precise stakeholder maps before scaling fieldwork. In Qatar specifically, HMC's centralized committee structure means a single institutional relationship can matter more than a broad physician survey, and misreading that relationship can stall a launch regardless of clinical merit.
Pilot qual often sharpens quant screeners in Qatar specialist pools. Sponsors who validate feasibility with two or three named specialists before fielding avoid the common trap of designing a survey for a population that does not exist at scale, and the resulting screeners are noticeably cleaner.
Link this page to the Qatar healthcare hub and company directory for internal planning. Confirm whether HMC, Sidra, or private networks are the priority stakeholder group before instruments are finalized, and align on which internal function owns the resulting action plan.
Healthcare market research in Qatar maps physician, payer, and hospital stakeholder behaviour under MOPH and HMC procurement context for launch and access decisions.
Yes. Harmonised GCC instruments allow side-by-side reads while preserving Qatar-specific MOPH and formulary logic.
Arabic–English screener logic, moderation, and reporting are standard for MENA programs including Qatar.
Specialists, hospital pharmacy leaders, formulary influencers, and procurement voices across HMC and private networks where therapy-relevant.
Use the healthcare market research hub, then open the dedicated Kuwait and UAE market research pages linked below.
HMC operates the majority of public tertiary and secondary care in Qatar, which means a single institution effectively sets much of the country's formulary and referral practice for most conditions. Research programmes map HMC's internal committee structure specifically rather than treating Qatar as a diffuse multi-provider market the way UAE or Saudi Arabia are.
Sidra Medicine focuses on women's and children's health and operates with a degree of clinical and procurement independence from the broader HMC network, so studies touching pediatric, maternal, or related specialty categories should treat Sidra as a distinct stakeholder group rather than folding it into general HMC assumptions.
Mandatory health insurance requirements for residents and visitors have expanded the privately insured population, creating access routes that run parallel to MOPH and HMC public pathways. Pricing and adoption research should specify which access route is being tested, since findings from the public pathway do not automatically apply to privately insured segments.
Given the small, concentrated specialist community in Doha, feasibility should be confirmed before a full quantitative sample is committed. A focused qualitative wave with named specialists can often be completed within two to three weeks, while broader quantitative studies typically run four to six weeks depending on scarcity.
Yes. Where a sponsor needs evidence to support a pricing or reimbursement conversation with MOPH or an HMC committee, we structure physician, pharmacist, and procurement findings into a format those reviewers can use directly rather than a generic commercial insight deck that would need to be re-worked before submission to either body.
Because expatriates make up the majority of Qatar's resident population, and their healthcare coverage depends heavily on employer-provided insurance and visa category, sizing models need to separate citizen and expatriate segments explicitly rather than applying a single national average that neither group represents accurately or usefully.
Yes. Qatar is frequently compared with Kuwait and Bahrain as compact, high-spend Gulf markets, and we can build harmonised instruments that allow a direct read across all three while preserving each market's distinct regulatory and institutional structure in the analysis rather than forcing an artificial like-for-like comparison.
Where a study requires HMC institutional approval to interview staff or access facility-level data, we build the approval timeline into the overall project schedule from the outset and communicate realistic milestones to the sponsor rather than treating approval as a formality that will not affect delivery dates in practice.
We flag this during the feasibility check rather than after fieldwork has started, and recommend switching to a qualitative-led design with a small number of in-depth expert interviews. This produces more defensible findings than forcing a quantitative sample that would compromise both response quality and statistical validity, and it is documented transparently in the proposal.
Name the brand, the country, and the breakdown your syndicated feed cannot give you. We send a project- and country-priced proposal — typically within 48 hours.
US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323